Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Peptide Knowledge Center
All peptides

Icatibant

Also known as: Firazyr
FDA-Approved

Icatibant is a selective bradykinin B2 receptor antagonist approved for acute attacks of hereditary angioedema (HAE) in adults.

Buy Icatibant on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Icatibant is a selective bradykinin B2 receptor antagonist approved for acute attacks of hereditary angioedema (HAE) in adults.

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

Competitively blocks bradykinin B2 receptors, halting bradykinin-mediated vascular permeability.

Current Research

FAST-1/2/3 pivotal trials support efficacy.
Research strength: Strong

Potential Medical Uses

  • Hereditary angioedema attacks

Potential Benefits

  • Rapid symptom relief
  • Self-administered

Known Side Effects

  • Injection-site reactions
  • Dizziness
  • Fever

Contraindications

  • Hypersensitivity

Drug Interactions

  • ACE inhibitors (theoretical antagonism)

Administration Methods

  • Subcutaneous injection

Half-life

~1–2 hours

Reconstitution

Prefilled syringe.

Storage & Handling

Room temperature.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.